Prescribing Information, including boxed warning

Patient Information

Talk to a Medical Expert

  • Medical Information Documents

  • Recent Congress Data

  • On Demand Medical Videos

    • Congress Data

      Utilizing and Applying Findings from Observational Studies in AIDS Research

      Shelly Dhir, PharmD Sr. Director, Portfolio Medical Lead
      Dr. Rick Elion, MD Director of Clinical Research, Washington Health Institute and Clinical Professor of Medicine George Washington University School of Medicine

      Using Fewer HIV Treatments When Treating HIV Long Term

      Andrew Zolopa, MD VP, Head, North American Medical Affairs ViiV Healthcare
      Dr. Babafemi Taiwo, MD, MBBS Gene Stollerman Professor of Medicine and Chief of the Division of Infectious Diseases Northwestern University

      DTG/3TC: Barrier to Resistance

      Jan van Lunzen, Head of Translational Medical Research

      Post-CROI 2021 Webinar

      Andrew Zolopa, MD, VP, Head, North America Medical Affairs

      GEMINI 144 Week: Efficacy and Safety

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

      TANGO 96 Week: Efficacy and Safety

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

      GEMINI 48 Week: Adherence Analysis

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

      STAT 24 Week: Feasibility, Efficacy and Safety

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    • Clinical Trials Data

      Using Fewer HIV Treatments When Treating HIV Long Term

      Andrew Zolopa, MD VP, Head, North American Medical Affairs ViiV Healthcare
      Dr. Babafemi Taiwo, MD, MBBS Gene Stollerman Professor of Medicine and Chief of the Division of Infectious Diseases Northwestern University

      Post-CROI 2021 Webinar

      Andrew Zolopa, MD, VP, Head, North America Medical Affairs

      GEMINI 144 Week: Efficacy and Safety

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

      TANGO 96 Week: Efficacy and Safety

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

      GEMINI 48 Week: Adherence Analysis

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

      STAT 24 Week: Feasibility, Efficacy and Safety

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    • Safety

      Post-CROI 2021 Webinar

      Andrew Zolopa, MD, VP, Head, North America Medical Affairs

      Antiretroviral Therapy and Weight Gain

      Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

    • Virology/Resistance

      DTG/3TC: Barrier to Resistance

      Jan van Lunzen, Head of Translational Medical Research

    • Real World Evidence

      Utilizing and Applying Findings from Observational Studies in AIDS Research

      Shelly Dhir, PharmD Sr. Director, Portfolio Medical Lead
      Dr. Rick Elion, MD Director of Clinical Research, Washington Health Institute and Clinical Professor of Medicine George Washington University School of Medicine

    • Treatment Naïve Data (GEMINI 1 & 2 Studies)

      Using Fewer HIV Treatments When Treating HIV Long Term

      Andrew Zolopa, MD VP, Head, North American Medical Affairs ViiV Healthcare
      Dr. Babafemi Taiwo, MD, MBBS Gene Stollerman Professor of Medicine and Chief of the Division of Infectious Diseases Northwestern University

      Year 3 Subgroup Analysis (CROI 2021)

    • Suppressed Switch Data

      TANGO Study

      Week 96 Subgroup Analyses